This book summarizes current knowledge on chronic lymphocytic leukemia (CLL), taking into account the most recent research. All aspects are considered, including pathophysiology, clinical presentation, diagnosis, prognosis, treatment, follow-up, and complications and their management. Readers will find important information on the various prognostic markers as well as practical guidance on the use of different diagnostic procedures. A key focus of the book is the changing treatment paradigm in CLL as progress in understanding of pathogenesis and pathophysiology leads to the identification of new potential therapeutic targets. General treatment concepts are clearly described, and it is explained how choice of treatment for CLL depends on stage, age, and performance status as well as specific genetic aberrations. In addition, frontline therapeutic strategies for disease relapse, including allogeneic stem cell transplantation, are reported. Looking beyond CLL, the diagnosis and therapy of T-cell prolymphocytic leukemia and T-cell large granular lymphocyte leukemia, two rare CLL-related entities, are addressed.
You can buy this product with a few simple clicks and have the file in your user profile forever.
AUTHORS: Michael Hallek Barbara Eichhorst Daniel Catovsky
YEAR: 2019
PAGES: 179
LANGUAGE: English
PUBLICATION: Springer, Cham
ISBN: 978-3-030-11392-6
$71,00 Original price was: $71,00.$3,00Current price is: $3,00.
Product Related
-75%
The Cuckoo’s Nest: Exploring the World of Psychotherapy through Film Original PDF 2026
-96%
Confronting Mental Health Stigma with AI and Machine Learning Original PDF 2026
-91%
Practical Handbook of Advanced Interventional Cardiology: Tips and Tricks 6th Original PDF 2026
-92%
The Coaching Psychology Handbook: Integrating Psychological Theory, Practice and Research Original PDF 2026
-94%
Biochip Design and Health Informatics Using IoT and SDN Original PDF 2026
-83%
CBT Frontline Action for Long-Term Conditions and Palliative Care A Guide for Care Professionals 2nd Edition Original PDF 2026
-95%